Skip to main
DWTX
DWTX logo

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. is focused on developing innovative antiviral therapies, particularly targeting conditions like fibromyalgia and long COVID, which positions the company favorably within the biotechnology sector. The recent licensing agreement with Serpin Pharma for the global rights to SP16 suggests a strategic expansion of Dogwood's portfolio, potentially enhancing future revenue streams. Furthermore, the upward revision of the 12-month price target to $12.00 per share underscores increased confidence in the company’s growth prospects, reflective of anticipated financial performance linked to its novel product candidates.

Bears say

Dogwood Therapeutics Inc, a biotechnology company developing antiviral therapies, faces challenges reflected in its limited financial performance, characterized by inconsistent revenue streams and ongoing expenditures associated with research and development. The company's product candidates, IMC-1 and IMC-2, while targeting significant market conditions like fibromyalgia and long COVID, remain in the clinical trial phase, which may prolong the path to generating revenue and profitability. Furthermore, the competitive landscape and high regulatory hurdles inherent in the biotechnology sector contribute to uncertainties regarding the successful commercialization of its therapies, impacting the stock’s attractiveness to investors.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.